Daniel Przybysz, Clinical Director and Head Of Radiation Oncology, Committee Member at NRG Oncology, shared a post on LinkedIn:
“IO+SRS for EGRF+ Brain Mets. Thanks to the International Association for the Study of Lung Cancer for the invitation to collaborate on this editorial. A lot to come, excited!”
Title: Osimertinib and Stereotactic Radiosurgery for EGFR-Mutant Brain Metastases
Author: Daniel Przybysz
